| References: |
Description of Dasatinib: Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity For the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic Forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
For the detailed information about the solubility of Dasatinib (BMS-354825) in water, the solubility of Dasatinib (BMS-354825) in DMSO, the solubility of Dasatinib (BMS-354825) in PBS buffer, the animal experiment（test） of Dasatinib (BMS-354825),the in vivo,in vitro and clinical trial test of Dasatinib (BMS-354825),the cell experiment（test） of Dasatinib (BMS-354825),the IC50, EC50 and Affinity of Dasatinib (BMS-354825), please contact DC Chemicals. |
